Trial Profile
A Post-Authorization Safety Study of Golimumab in Ulcerative Colitis Using the Spanish ENEIDA Registry
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Sep 2018
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Acronyms EUPAS15752
- Sponsors Merck Sharp & Dohme
- 23 Sep 2018 New trial record
- 26 Aug 2018 Results (n=1441 as of May 2017) presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.